John Libbey Eurotext

My cart ( )

Bulletin du Cancer

EGFR/HER1: a target life Volume 99, numéro 2, Février 2012

Résumé : EGFR may be considered as an old target, which can be inhibited both by monoclonal antibodies and tyrosine kinase inhibitors. Those molecular targeted strategies are now approved in a wild range of tumors: colorectal cancer, lung cancer, pancreatic cancer and head and neck cancer. This paper proposes to describe the development of anti-EGFR drugs, highlighting several strategies points. Predicting biomarkers have been extensively studied for these agents, sustaining the hallmarks of the development of molecular targeting drugs.

Illustrations

Ouvrir l'onglet